|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The colonic lamina propria from patients with CD was infiltrated by T cells and had higher levels of sCYLD (but not full-length CYLD) and SMAD7 than tissues from controls.
|
30315770 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Smad7, a negative regulator of TGF-β signaling, has been implicated in the pathogenesis and treatment of inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC).
|
31553906 |
2019 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An antisense oligonucleotide against SMAD7 mRNA (mongersen) demonstrated pre-clinical and phase II efficacy in CD, but a phase III clinical trial was stopped due to lack of efficacy.
|
31068803 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the efficacy and safety of GED-0301, an antisense oligodeoxynucleotide to Smad7, in active Crohn's disease (CD).
|
31850931 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In Crohn's disease (CD), the pathogenic immune response is associated with high Smad7, an inhibitor of TGF-β1 signaling.
|
29668937 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Smad7 is a negative regulator of transforming growth factor-β, which is increased in the intestinal mucosa of patients with active Crohn's disease (CD).
|
28847751 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The high SMAD7 immunoreactivity and lack of p-SMAD3 expression in the LP suggests defective TGF-β signaling in the LP in EE similar to a previously reported SMAD7-mediated inflammatory pathway in refractory CD and Crohn's disease.
|
29415065 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are multiple emerging mechanisms of action, including Janus kinase inhibition, Smad7 inhibition, and sphingosine-1-phosphate receptor modulators, that are administered as oral medications, and small molecules represent the next generation of therapies for Crohn's disease.
|
28838419 |
2017 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mongersen was utilized in patients with Crohn's disease and accelerates the degradation of SMAD7 mRNA, which consequently strengthens the mainly anti-inflammatory signalling pathway of transforming growth factor β1.
|
29051788 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite a successful clinical trial with an oral Smad7 antisense oligonucleotide in CD, intraarticular (i.a.) modulation of Smad7 expression has not been performed in rheumatoid joint yet.
|
27731365 |
2016 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings together with the demonstration that Smad7 antisense oligonucleotide is safe and well-tolerated in patients with Crohn's disease indicate that Smad7 antisense oligonucleotide-based pharmaceutical compounds could enter the therapeutic armamentarium of these disorders.
|
23287011 |
2013 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article we summarize the data supporting the pathogenic role of Smad7 in IBD and discuss the recent results of the use of GED0301 in CD.
|
23489130 |
2013 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also analyzed TIMP-3 levels in lamina propria mononuclear cells (LPMCs) collected from biopsy samples of individuals with or without CD (controls) and then stimulated with transforming growth factor (TGF)-β1, as well as in biopsy samples collected from patients with CD and then incubated with a Smad7 anti-sense oligonucleotide (knock down).
|
22819866 |
2012 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease.
|
22252452 |
2012 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease.
|
22971085 |
2012 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The effect of p300 silencing on Smad7 expression was determined in Crohn's disease lamina propria mononuclear cells.
|
16285943 |
2005 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
TGF-beta1 cannot inhibit proinflammatory cytokine production in isolated lamina propria mononuclear cells from patients with Crohn disease (CD), but inhibition of Smad7 restores TGF-beta1 signaling and enables TGF-beta1 to inhibit cytokine production.
|
11518734 |
2001 |